In vitro hydroxyurea decreases Th1 cell-mediated immunity.
Hydroxyurea (HU) is used in the treatment of hematologic disorders and is sometimes added to antiretroviral combination therapy to potentiate human immunodeficiency virus (HIV) suppression. However, HU has toxic effects on rapidly dividing cells, including the effectors of the immune response. To determine whether HU affects specific T-cell responses, we measured lymphocyte proliferation and cytokine production in response to microbial antigen and mitogen stimulation in the presence of added HU (10 to 1,000 microM). HU treatment of peripheral blood mononuclear cells obtained from HIV-infected patients and uninfected controls decreased lymphocyte proliferation and gamma interferon production compared with untreated cells. Interleukin-2 (IL-2) and IL-10 production was not affected by HU. The HU-mediated decrease of lymphocyte proliferation was similar in peripheral blood mononuclear cells from HIV-infected patients and from uninfected controls. The inhibitory effect of HU required continuous exposure to the drug and could be reverted by washing the drug out of the culture environment. These findings suggest that HU-containing therapeutic regimens might decrease Th1-cell-mediated immune responses in vivo.
Weinberg
A
A
Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. adriana.weinberg@uchsc.edu
D002455:Cell Division / Q000187:drug effects; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology*; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D018417:Th1 Cells / Q000187:drug effects* / Q000276:immunology
D007376:Interleukin-2; D016753:Interleukin-10; D007371:Interferon-gamma; D006918:Hydroxyurea